Compare Amphastar Pharmaceuticals Inc (AMPH) vs GE Vernova Inc (GEV) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

GE Vernova (GEV) trades at $1,091.57, up 1.52% with strong analyst support (75% buy ratings) and a consensus price target of $1,230. The stock shows bullish technical momentum with recent earnings beats and robust profitability metrics including 23.81% net income margin and 83.23% ROE. Recent news highlights the company's strategic positioning in AI power infrastructure and nuclear energy expansion.

Outlook remains positive with projected revenue growth to $39.4B and net profit doubling to $9.4B in 2026. Key risks include high valuation multiples (P/E 31.9, EV/EBITDA 113.7) and execution challenges in scaling nuclear operations. The stock offers exposure to AI-driven power demand but faces volatility from energy market fluctuations.